February 27, 2007--EvoGenix will apply its proprietary technologies for antibody humanization and optimization to assist Vegenics in developing an antibody therapeutic product targeting VEGF-D, which may prove to be an important target for treating certain forms of cancer. Vegenics will have the right to commercialize the product developed as a result of the collaboration.

In addition to research payments, EvoGenix will earn milestone payments and a royalty on product sales subject to marketing approval being received. EvoGenix